FR11C0022I2 - HUMAN PAPILLOMA VIRUS CAPSID PROTEIN PRODUCTION AND VIRAL-LIKE PARTICLES - Google Patents

HUMAN PAPILLOMA VIRUS CAPSID PROTEIN PRODUCTION AND VIRAL-LIKE PARTICLES

Info

Publication number
FR11C0022I2
FR11C0022I2 FR11C0022C FR11C0022C FR11C0022I2 FR 11C0022 I2 FR11C0022 I2 FR 11C0022I2 FR 11C0022 C FR11C0022 C FR 11C0022C FR 11C0022 C FR11C0022 C FR 11C0022C FR 11C0022 I2 FR11C0022 I2 FR 11C0022I2
Authority
FR
France
Prior art keywords
viral
particles
capsid protein
protein production
papilloma virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0022C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0022(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Publication of FR11C0022I1 publication Critical patent/FR11C0022I1/fr
Application filed by University of Rochester filed Critical University of Rochester
Application granted granted Critical
Publication of FR11C0022I2 publication Critical patent/FR11C0022I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to a method of expressing the papillomavirus capsid protein coding sequence in a cell using an expression system under conditions facilitating expression of the protein in the cell. In another aspect of the invention, it has been discovered that virus-like particle(s) (VLPs), fragment(s), capsomer(s) or portion(s) thereof are formed from the papillomavirus capsid
FR11C0022C 1993-03-09 2011-07-04 HUMAN PAPILLOMA VIRUS CAPSID PROTEIN PRODUCTION AND VIRAL-LIKE PARTICLES Active FR11C0022I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07
EP94912186A EP0688227B1 (en) 1993-03-09 1994-03-08 Production of human papillomavirus capsid protein and virus-like particles

Publications (2)

Publication Number Publication Date
FR11C0022I1 FR11C0022I1 (en) 2011-05-08
FR11C0022I2 true FR11C0022I2 (en) 2012-08-03

Family

ID=26703787

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0022C Active FR11C0022I2 (en) 1993-03-09 2011-07-04 HUMAN PAPILLOMA VIRUS CAPSID PROTEIN PRODUCTION AND VIRAL-LIKE PARTICLES

Country Status (14)

Country Link
EP (3) EP1588713B1 (en)
JP (4) JPH08507685A (en)
AT (3) ATE494005T1 (en)
AU (3) AU688759C (en)
CA (1) CA2157932C (en)
DE (9) DE05075889T1 (en)
DK (2) DK1618888T3 (en)
ES (3) ES2263405T3 (en)
FR (1) FR11C0022I2 (en)
HK (2) HK1082196A1 (en)
LU (3) LU91313I2 (en)
NL (3) NL300265I2 (en)
PT (2) PT1618888E (en)
WO (1) WO1994020137A1 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000017I1 (en) 1991-07-19 2007-07-26 Univ Queensland Vaccines against papillomavirus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (en) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomaviruses, means for their detection and for the therapy of diseases caused by them
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
ES2264563T3 (en) * 1994-10-07 2007-01-01 Loyola University Of Chicago PARTICLES SIMILAR TO THE PAPILOMA VIRUS, FUSION PROTEINS AND PROCEDURE FOR PREPARATION.
AR004464A1 (en) * 1994-11-14 1998-12-16 Merck Sharp & Dohme A METHOD FOR PRODUCING A PAPILOMAVIRUS CAPSIDE PROTEIN
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ES2213185T3 (en) * 1995-11-15 2004-08-16 MERCK & CO., INC. SYNTHETIC VIRUS HPV11 TYPE PARTICLES.
DE19543553B4 (en) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP antigens of the JC virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (en) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc PSEUDO-PARTICLES VIRALES USEFUL AS A VECTOR OF NUCLEIC ACID DELIVERY
JP2001506485A (en) * 1996-10-04 2001-05-22 メルク エンド カンパニー インコーポレーテッド Synthetic HPV16 virus-like particles
ES2213841T3 (en) * 1996-12-09 2004-09-01 MERCK & CO., INC. SYNTHETIC PARTICLES SIMILAR TO HPV16 VIRUS.
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925199A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy
DE19925235A1 (en) 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy
AU2001294565A1 (en) * 2000-09-18 2002-04-02 Med Immune, Inc. In vitro assay for measuring the immunogenicity of a vaccine
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
ATE471990T1 (en) 2001-08-13 2010-07-15 Univ Rochester TRANSCUTANE IMMUNIZATION AGAINST PAPILLOMAVIRUS WITH VIRUS-LIKE PAPILLOMAVIRUS PARTICLES
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (en) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
WO2008082719A2 (en) 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2068918T4 (en) 2006-09-26 2024-09-02 Access To Advanced Health Inst VACCINE COMPOSITION COMPRISING SYNTHETIC ADJUVANT
EA021391B1 (en) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Method of raising an immune response, vaccine composition, use thereof and kit
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
CN101293918B (en) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 Shorten human papilloma virus 16 type L1 protein
WO2008145021A1 (en) 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
EP2907821B1 (en) 2007-05-29 2016-12-28 Xiamen University Method for producing a N-terminaly truncated L1 protein of human papillomavirus (HPV)
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
CN106377767A (en) 2008-05-26 2017-02-08 卡迪拉保健有限公司 Combined measles-human papilloma vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
JP6054942B2 (en) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション Immunogenic compositions and methods of using the compositions to elicit humoral and cellular immune responses
PL2811981T3 (en) 2012-02-07 2019-09-30 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
CN107540730B (en) 2012-05-16 2021-07-16 免疫设计公司 Vaccines for HSV-2
CN109134640A (en) 2012-10-23 2019-01-04 爱默蕾大学 GM-CSF and IL-4 conjugates, composition and relative method
BR112015025709A2 (en) 2013-04-18 2017-07-18 Immune Design Corp gla monotherapy for cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR102411781B1 (en) 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Single vial vaccine formulations
CA3010905A1 (en) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
ES2929054T3 (en) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
WO2017210364A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
KR102673794B1 (en) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 Nanostructured lipid carriers and stable emulsions and their uses
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
WO2022171681A1 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116375816B (en) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 Human papilloma virus 56 type L1 protein mutant, method for reducing degradation of recombinant protein and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
DE122007000017I1 (en) * 1991-07-19 2007-07-26 Univ Queensland Vaccines against papillomavirus

Also Published As

Publication number Publication date
NL300265I1 (en) 2007-05-01
CA2157932C (en) 2011-10-11
EP1588713B1 (en) 2010-12-22
HK1082206A1 (en) 2006-06-02
DE122007000089I1 (en) 2008-03-27
JP5306251B2 (en) 2013-10-02
ES2263405T1 (en) 2006-12-16
DK0688227T3 (en) 2005-06-27
LU91313I2 (en) 2007-04-23
JP2010148514A (en) 2010-07-08
WO1994020137A1 (en) 1994-09-15
EP1618888A1 (en) 2006-01-25
ES2263406T1 (en) 2006-12-16
AU688759B2 (en) 1998-03-19
DE122007000014I1 (en) 2007-05-24
AU688759C (en) 2006-12-21
ATE494005T1 (en) 2011-01-15
ES2242955T3 (en) 2005-11-16
AU6443694A (en) 1994-09-26
EP1618888B1 (en) 2011-01-05
AU2007201005A1 (en) 2007-03-29
ATE296111T1 (en) 2005-06-15
DE69434383T2 (en) 2005-11-24
FR11C0022I1 (en) 2011-05-08
EP0688227A4 (en) 1996-05-29
DK1618888T3 (en) 2011-04-04
NL300309I1 (en) 2008-02-01
DE69434383D1 (en) 2005-06-30
EP0688227B1 (en) 2005-05-25
JP2010099091A (en) 2010-05-06
HK1082196A1 (en) 2006-06-02
JP2007075117A (en) 2007-03-29
JP4486075B2 (en) 2010-06-23
AU2007201005B2 (en) 2010-06-10
CA2157932A1 (en) 1994-09-15
ES2263405T3 (en) 2011-04-20
DE05075369T1 (en) 2006-11-16
PT688227E (en) 2005-10-31
DE05075889T1 (en) 2006-10-05
NL300265I2 (en) 2008-05-01
DE122011100018I1 (en) 2011-11-17
JPH08507685A (en) 1996-08-20
PT1618888E (en) 2011-04-08
AU2007201006A1 (en) 2007-03-29
ES2242955T4 (en) 2010-04-12
EP1588713A1 (en) 2005-10-26
DE122007000090I1 (en) 2008-03-27
ATE492289T1 (en) 2011-01-15
DE69435332D1 (en) 2011-02-17
JP5386392B2 (en) 2014-01-15
DE69435331D1 (en) 2011-02-03
LU91391I2 (en) 2008-02-14
NL300309I2 (en) 2008-03-03
ES2263406T3 (en) 2011-06-06
EP0688227A1 (en) 1995-12-27
LU91392I2 (en) 2008-02-14
AU2007201006B2 (en) 2010-07-01
NL300310I1 (en) 2008-02-01

Similar Documents

Publication Publication Date Title
FR11C0022I2 (en) HUMAN PAPILLOMA VIRUS CAPSID PROTEIN PRODUCTION AND VIRAL-LIKE PARTICLES
NL300323I2 (en) Papillomavirus-like particles, fusion proteins, and method for their preparation
NL300313I1 (en) Human papillomavirus vaccine
WO1999061052A3 (en) Oral immunization with papillomavirus virus-like particles
WO1997004099A3 (en) Papillomaviruses, agents for detecting them and for treating diseases caused by such viruses
DK0750669T3 (en) Modified papillomavirus L2 protein and VLPs formed therefrom